9 jan 2023
JPMorgan presentation
Potential for indication expansion: Literature reports of CAIX expression
Glioblastoma Multiforme
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma
Gastric Cancer
Pancreatic Ductal Adenocarcinoma
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Cancer
Small Cell Lung Cancer
Cholangio-carcinoma
Soft Tissue Sarcoma
Epithelial Ovarian Cancer
Colorectal Cancer
Ann: Phase II study for indication expansion of TLX250-CDx doses, page-7
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.27 |
Change
0.120(0.66%) |
Mkt cap ! $6.122B | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.31 | $17.92 | $10.03M | 554.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1177 | $18.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.27 | 491 | 8 |
View Market Depth
| Last trade - 13.54pm 11/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |